Singapore, May 12 -- Japan-based pharma firm Kyowa Kirin has announced plans to create a state-of-the-art research hub, to further improve its capabilities in drug discovery. The plan is to integrate two existing sites, the Fuji Site and Tokyo Research Park, into a new integrated research hub at Yokohama Business Park.

Specific conditions and the implementation schedule will be determined through further reviews with relevant stakeholders. Following the potential launch of the new research hub, Kyowa Kirin is considering the closure of both the Fuji Site and Tokyo Research Park.

As drug discovery environments become increasingly challenging due to the emergence of new modalities, advances in AI, and growing technological complexity, Kyo...